Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Luye Pharma Group Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public

Established: 2014-04-28

Employees: 5.2K

Market Cap: -

Website: http://www.luye.cn

Clinical Trials

Comparative Efficacy, Safety, PK, and Immunogenicity Study

Phase 3

Active, not recruiting

Conditions: Osteoporosis, Postmenopausal

Interventions: Biological: Denosumab

First Posted Date: 2023-05-10

Last Posted Date: 2024-04-26

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 392

Registration Number: NCT05853354

Locations: 🇺🇸
Clinical Trials Management Services, LLC, Thousand Oaks, California, United States
🇺🇸
Indago Research and Health Center, Inc., Hialeah, Florida, United States
🇺🇸
Valley Institute of Research, Fort Worth, Texas, United States

and more 30 locations

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: RID-TDS 13.3 mg/24 h
Drug: Exelon® 13.3 mg/24 h

First Posted Date: 2023-05-10

Last Posted Date: 2023-10-19

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 48

Registration Number: NCT05853341

Locations: 🇩🇪
SocraTec R&D GmbH, Clinical Pharmacology Unit, Erfurt, Thüringen, Germany

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Phase 1

Completed

Conditions: Physiological Effects of Drugs
Psychotic Disorders
Tranquilizing Agents
Schizophrenia
Mood Disorders
Mental Disorders
Antipsychotic Agents
Schizophrenia Spectrum and Other Psychotic Disorders
Central Nervous System Depression
Neurotransmitter Agents

Interventions: Drug: LY03010 156 mg treatment group, gluteal
Drug: LY03010 156 mg treatment group, deltoid
Drug: LY03010 351 mg treatment group, deltoid
Drug: LY03010 351 mg treatment group, gluteal

First Posted Date: 2022-04-11

Last Posted Date: 2024-03-19

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 89

Registration Number: NCT05321602

Locations: 🇺🇸
Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸
CNS Research, Garden Grove, California, United States
🇺🇸
NRC Research Institute, Orange, California, United States

and more 6 locations

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

Phase 1

Completed

Conditions: Tardive Dyskinesia
Huntington Disease

Interventions: Drug: LPM3770164 sustained release tablet
Drug: LPM3770164 sustained release tablet simulant

First Posted Date: 2022-02-14

Last Posted Date: 2024-01-29

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 104

Registration Number: NCT05238701

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: ZOLADEX® 3.6 mg
Drug: LY01005

First Posted Date: 2021-12-01

Last Posted Date: 2023-05-16

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 23

Registration Number: NCT05140512

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: ZOLADEX® 3.6 mg
Drug: LY01005

First Posted Date: 2021-11-05

Last Posted Date: 2023-05-16

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 188

Registration Number: NCT05110170

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China

A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture

Phase 3

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: LY06006

First Posted Date: 2021-09-29

Last Posted Date: 2021-09-29

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 448

Registration Number: NCT05060406

Locations: 🇨🇳
Shanghai Sixth People's Hospital, Shanghai, Shanghai, China

A Study to Evaluate LY06006 and Prolia in Healthy Adults

Phase 1

Conditions: Healthy Adults

Interventions: Drug: Prolia
Drug: LY06006

First Posted Date: 2021-07-22

Last Posted Date: 2021-07-22

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 168

Registration Number: NCT04973722

Locations: 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China

A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects

Phase 1

Conditions: Covid19

Interventions: Drug: LY-CovMab

First Posted Date: 2021-07-22

Last Posted Date: 2021-07-22

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 42

Registration Number: NCT04973735

Locations: 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China

Relative Bioavailability of LY03010 Compared to Listed Drug

Phase 1

Completed

Conditions: Schizophrenia Spectrum
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Neurotransmitter Agents
Antipsychotic Agents
Tranquilizing Agents
Schizophrenia
Psychotic Disorders
Mood Disorders

Interventions: Drug: INVEGA SUSTENNA
Drug: LY03010; paliperidone palmitate

First Posted Date: 2021-06-10

Last Posted Date: 2023-04-25

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 281

Registration Number: NCT04922593

Locations: 🇺🇸
Collaborative Neuroscience Network, Inc., Garden Grove, California, United States
🇺🇸
Synergy San Diego, Lemon Grove, California, United States
🇺🇸
CNS Network, LLC, Torrance, California, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy